Qing Hai Zhao
Corporate Officer/Principal bij ADAGENE INC.
Actieve functies van Qing Hai Zhao
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ADAGENE INC. | Corporate Officer/Principal | 01-10-2020 | - |
Loopbaan van Qing Hai Zhao
Eerdere bekende functies van Qing Hai Zhao
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FORTY SEVEN, INC. | Corporate Officer/Principal | 01-01-2017 | 01-10-2020 |
| ANAPTYSBIO, INC. | Corporate Officer/Principal | 01-01-2016 | 01-01-2017 |
| NGM BIOPHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-01-2014 | 01-01-2016 |
| Corporate Officer/Principal | 01-01-2014 | 01-01-2016 |
Opleiding van Qing Hai Zhao
| East China University of Science & Technology | Undergraduate Degree |
| University of Uppsala | Doctorate Degree |
| Zhongshan Hospital Fudan University | Graduate Degree |
Statistieken
Internationaal
| China | 4 |
| Verenigde Staten | 4 |
| Zweden | 2 |
Operationeel
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ADAGENE INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
- Beurs
- Insiders
- Qing Hai Zhao
- Ervaring
